Thalidomide-induced limb defects: resolving a 50-year-old puzzle

Neil Vargesson (Corresponding Author)

Research output: Contribution to journalLiterature review

90 Citations (Scopus)

Abstract

Despite the recent discovery that thalidomide causes limb defects by targeting highly angiogenic, immature blood vessels, several challenges still remain and new ones have arisen. These include understanding the drug's species specificity, determining molecular target(s) in the endothelial cell, shedding light on the molecular basis of phocomelia and producing a form of the drug that is clinically effective without having side effects. Now that the trigger of thalidomide-induced teratogenesis has been uncovered, a framework is proposed, incorporating and uniting previous models of thalidomide action, explaining how thalidomide causes not just limb defects, but also all the other defects it induces.
Original languageEnglish
Pages (from-to)1327-1336
Number of pages10
JournalBioEssays
Volume31
Issue number12
Early online date17 Nov 2009
DOIs
Publication statusPublished - Dec 2009

Keywords

  • thalidomide
  • chick limb development
  • CPS49
  • phocomelia
  • thalidomide analogue
  • therapeutics

Fingerprint Dive into the research topics of 'Thalidomide-induced limb defects: resolving a 50-year-old puzzle'. Together they form a unique fingerprint.

  • Cite this